The major upregulations identified in this tumor comprise muscle-specific gene products (transcription factors: CAAC binding; proteomics: transgelin, transgelin-2; RNA: anoctamin-4; and immunohistochemistry: smooth muscle actin) and calcium-regulating molecules (proteomics: calumenin, S100-A11, reticulocalbin-3, and 78 kD glucose-regulated protein). This evidence concerns the gene CALU and neoplasm.